Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 5Recruiting 3Terminated 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 37Neoplasm Metastasis 6Neoplasms 3Ovarian Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Breast Diseases 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Neoplasms by Site 1Medulloblastoma 1Lung Neoplasms 1Locoregional Recurrence 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Head and Neck Neoplasms 1HR+/HER2- Breast Cancer 1HER2 Negative Breast Cancer 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1ER+ HER2- Advanced Breast Cancer 1Digestive System Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 38Blood Specimen Collection 38Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 17Exercise 17Carboplatin 17Nivolumab 15atezolizumab 14Paclitaxel 14Cisplatin 14Drug Therapy 13Fluorouracil 12Cyclophosphamide 12Cetuximab 11Trastuzumab 10Pemetrexed 10Leucovorin 10Docetaxel 10Dexamethasone 10Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × ribociclib × Clear all
NCT05768139 2026-05-22

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡